Links
- ORCID
- ORCID
- ORCID
- ORCID
- Crossref | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [researchonline.lshtm.ac.uk] | PDF
- [europepmc.org] | PDF
Tools
A Randomized, Double-Blind Placebo Controlled Trial of Balapiravir, a Polymerase Inhibitor, in Adult Dengue Patients
Journal article published in 2012 by
Nguyet Minh Nguyen 
,
Chau Nguyen Bich Tran,
Lam Khanh Phung,
Kien Thi Hue Duong,
Huy Le Anh Huynh,
Jeremy Farrar,
Quyen Than Ha Nguyen,
Hien Tinh Tran,
Chau Van Vinh Nguyen,
Chau Van Vinh Nguyen,
Laura Merson ,
Long Truong Hoang,
Martin L. Hibberd,
Pauline P. K. Aw,
Andreas Wilm
and other authors.
,
Chau Nguyen Bich Tran,
Lam Khanh Phung,
Kien Thi Hue Duong,
Huy Le Anh Huynh,
Jeremy Farrar,
Quyen Than Ha Nguyen,
Hien Tinh Tran,
Chau Van Vinh Nguyen,
Chau Van Vinh Nguyen,
Laura Merson ,
Long Truong Hoang,
Martin L. Hibberd,
Pauline P. K. Aw,
Andreas Wilm
and other authors.
Abstract
BACKGROUND: Dengue is the most common arboviral infection of humans. There are currently no specific treatments for dengue. Balapiravir is a prodrug of a nucleoside analogue (called R1479) and an inhibitor of hepatitis C virus replication in vivo. METHODS: We conducted in vitro experiments to determine the potency of balapiravir against dengue viruses and then an exploratory, dose-escalating, randomized placebo-controlled trial in adult male patients with dengue with